xmlui.ArtifactBrowser.ItemViewer.show_simple

dc.contributor.authorSilva, Desirée Lopes da-
dc.contributor.authorNunes, Heloisa Marceliano-
dc.contributor.authorFreitas, Pedro Eduardo Bonfim-
dc.date.accessioned2021-02-01T18:28:35Z-
dc.date.available2021-02-01T18:28:35Z-
dc.date.issued2021-
dc.identifier.citationSILVA, Desirée Lopes da; NUNES, Heloisa Marceliano; FREITAS, Pedro Eduardo Bonfim. Natural prevalence of NS3 gene resistance-associated substitutions (RASs) in patients with chronic hepatitis C from the state of Para/Brazil. Virus Research, v. 292, n. xx, p. xx, Jan. 2021.pt_BR
dc.identifier.issn0168-1702-
dc.identifier.urihttp://patua.iec.gov.br//handle/iec/4234-
dc.description.abstractThe resistance of hepatitis C virus (HCV) to direct-acting antiviral agents, used in chronic hepatitis C treatment, consists of a natural process resulting from resistance-associated substitutions (RASs) at specific amino acid regions. To identify and establish the natural prevalence of RASs in the NS3 gene in patients with chronic hepatitis C in the state of Pará, northern Brazil. Molecular analysis was performed on a total of 35 patients infected with HCV genotype 1, who were treatment-naive to protease inhibitors. HCV RNA was extracted from plasma and the NS3 region was amplified and submitted to DNA sequencing (Sanger). The general natural prevalence of RASs in the NS3 gene was 37.5 % (Y56F and S122T). The substitutions Y56F (34.3 %), S122T (3.1 %), V132I (15.6 %) and V170I (9.3 %) were identified. Y56F and S122T provide resistance to the protease inhibitors grazoprevir and simeprevir, respectively. All amino acid substitutions in the NS3 gene, including RASs, identified in patients from the state of Pará were present in other Brazilian studies. The natural presence of RASs in this study reflects the elevated genetic variability of HCV.pt_BR
dc.language.isoengpt_BR
dc.publisherElsevierpt_BR
dc.rightsAcesso Embargadopt_BR
dc.titleNatural prevalence of NS3 gene resistance-associated substitutions (RASs) in patients with chronic hepatitis C from the state of Para/Brazilpt_BR
dc.typeArtigopt_BR
dc.subject.decsPrimaryHepatite C Crônica / patologiapt_BR
dc.subject.decsPrimaryHepacivirus / genéticapt_BR
dc.subject.decsPrimaryResistência a Medicamentos / genéticapt_BR
dc.subject.decsPrimaryAntiviraispt_BR
dc.subject.decsPrimaryInibidores de Proteasespt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Ananindeua, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Ananindeua, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Ananindeua, PA, Brasil.pt_BR
dc.identifier.doi10.1016/j.virusres.2020.198251-


xmlui.dri2xhtml.METS-1.0.item-files-head

Thumbnail

xmlui.ArtifactBrowser.ItemViewer.head_parent_collections

xmlui.ArtifactBrowser.ItemViewer.show_simple